top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

pharmafile | September 25, 2020 | News story | Medical Communications  

The top 10 news stories this week focus on coronavirus vaccine trials, as around one in seven patients who have received Russia’s vaccine against COVID-19 have displayed side-effects in clinical studies and voices in the scientific community are calling for more transparency from AstraZeneca about their Oxford vaccine trials.

In other news, Public Health England has warned that catching seasonal flu and coronavirus at the same time could almost double the risk of death, while the Centers for Disease Control and Prevention has identified nearly 11,000 people who were potentially exposed to coronavirus while flying on commercial airlines.

1. Fujifilm’s Avigan reduces recovery time in non-severe COVID-19 patients

Fujifilm has announced promising new Phase 3 findings demonstrating that its antiviral therapy Avigan (favipravir) had a statistically significant impact on recovery times in COVID-19 patients with non-severe symptoms.

2. Contracting flu and COVID-19 simultaneously increases the risk of death, new study shows

Public Health England has warned that catching seasonal flu and coronavirus at the same time could almost double the risk of death.

3. Science community calls for transparency on AstraZeneca’s halted US COVID-19 vaccine trial

The halting of AstraZeneca’s COVID-19 vaccine trial around the world was cause for much initial concern over the eventual safety and efficacy of the therapy. Trials have resumed in the UK, Brazil and South Africa, but US trials remain on hold. Now, voices in the scientific community are calling for transparency from the trial organisers as to why.

4. FDA set to announce stricter criteria for COVID-19 vaccines to receive Emergency Use Authorization

The FDA is set to release new guidelines that would raise safety and efficacy requirements required for a COVID-19 vaccine to be granted Emergency Use Authorization.

5. Roche says its rheumatoid arthritis drug reduces the need for ventilators in coronavirus patients

Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put on a ventilator.

6. One in seven Russian COVID-19 vaccine recipients display side-effects, says Health Minister

Around one in seven patients who have received Russia’s vaccine against COVID-19 have displayed side-effects in clinical studies, according to the country’s Health Minister.

7. AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.

8. CDC says nearly 11,000 Americans have been exposed to COVID-19 on flights

The Centers for Disease Control and Prevention has identified nearly 11,000 people who were potentially exposed to coronavirus while flying.

9. New York files $2 billion lawsuit against J&J for downplaying risks of opioids in its marketing

New York State is suing Johnson & Johnson in a lawsuit seeking $2 billion in damages for the company’s role in the opioid crisis.

10. New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Related Content

No items found

Latest content